Importantly, this study does not provide us any guidance regarding a young postmenopausal
patient who has had a change in health status, such as a newly diagnosed autoimmune disease necessitating treatment with oral steroids, or after discontinuation of systemic menopausal hormone therapy, for whom repeating BMD assessment within 2 years or even 1 year of the initial study can be clinically justified despite evidence of normal BMD on her baseline scan.
List of Tables Table 1: Sources of Prevalence Data Used in the Epidemiology Forecast 11 Table 2: 7MM, Prevalent Cases of Postmenopausal
Vaginal Atrophy, N, Select Years, 2012-2022 16 Table 3: 7MM, Calculated Total Prevalence of Postmenopausal
Vaginal Atrophy, By Age, %, 2012-2022 18 Table 4: 7MM, Prevalent Cases of Postmenopausal
Vaginal Atrophy, By Age, N, 2012 18 Table 5: 7MM, Prevalent Cases of Postmenopausal
Vaginal Atrophy, By Severity, N (Row %), 2012 20
women face an even greater risk because estrogen, a hormone that helps keep bone remodelling in balance, decreases after menopause.
Analysis was performed on 847,982 postmenopausal
women; 433,178 (51.
Intravaginal DHEA and Sexual Function in Postmenopausal
Zhai and colleagues investigated the natural history of postmenopausal
bone loss among almost 1000 Caucasian females from Chingford in the United Kingdom who had at least two bone density tests over a 15-year period.
6 minutes) or of postmenopausal
women who were taking hormone therapy (a difference of 5.
prevention and treatment of osteoporosis in postmenopausal
Estradiol is most prominent during a women's reproductive years, and the weaker estrone, is more prominent in postmenopausal
The researchers estimate that a single four-ounce glass of red wine daily could provide enough procyanidin B dimers to inhibit aromatase activity in the average postmenopausal
Predictors of difficulty when discontinuing postmenopausal
In the 6-8 months after publication of findings from the Women's Health Initiative on the risks associated with postmenopausal
hormone therapy, more than half of women in a large California health plan who had been regularly using hormone therapy tried to stop, even though two-thirds overall did not know what the study's main findings were, according to a survey of female members of the plan.